546 related articles for article (PubMed ID: 26549336)
21. Safety profile of hymenoptera venom immunotherapy (VIT) in monosensitized patients: lack of new sensitization to nontreated insect venom.
Spoerl D; Bircher AJ; Scherer K
J Investig Allergol Clin Immunol; 2011; 21(1):22-7. PubMed ID: 21370719
[TBL] [Abstract][Full Text] [Related]
22. Immunotherapy with honeybee venom and yellow jacket venom is different regarding efficacy and safety.
Müller U; Helbling A; Berchtold E
J Allergy Clin Immunol; 1992 Feb; 89(2):529-35. PubMed ID: 1740583
[TBL] [Abstract][Full Text] [Related]
23. Predictors of clinical effectiveness of Hymenoptera venom immunotherapy.
Ruëff F; Vos B; Oude Elberink J; Bender A; Chatelain R; Dugas-Breit S; Horny HP; Küchenhoff H; Linhardt A; Mastnik S; Sotlar K; Stretz E; Vollrath R; Przybilla B; Flaig M
Clin Exp Allergy; 2014; 44(5):736-46. PubMed ID: 24447114
[TBL] [Abstract][Full Text] [Related]
24. Venom immunotherapy improves health-related quality of life in patients allergic to yellow jacket venom.
Oude Elberink JN; De Monchy JG; Van Der Heide S; Guyatt GH; Dubois AE
J Allergy Clin Immunol; 2002 Jul; 110(1):174-82. PubMed ID: 12110838
[TBL] [Abstract][Full Text] [Related]
25. Immunoblot studies in allergic patients to hymenoptera venom before and during immunotherapy.
Pereira Santos MC; Pedro E; Spínola Santos A; Branco Ferreira M; Palma Carlos ML; Palma Carlos AG
Eur Ann Allergy Clin Immunol; 2005 Sep; 37(7):273-8. PubMed ID: 16285233
[TBL] [Abstract][Full Text] [Related]
26. Venom immunotherapy in patients with clonal mast cell disorders: efficacy, safety, and practical considerations.
Bonadonna P; Gonzalez-de-Olano D; Zanotti R; Riccio A; De Ferrari L; Lombardo C; Rogkakou A; Escribano L; Alvarez-Twose I; Matito A; Vega A; Passalacqua G
J Allergy Clin Immunol Pract; 2013; 1(5):474-8. PubMed ID: 24565619
[TBL] [Abstract][Full Text] [Related]
27. Mastocytosis and insect venom allergy.
Bonadonna P; Zanotti R; Müller U
Curr Opin Allergy Clin Immunol; 2010 Aug; 10(4):347-53. PubMed ID: 20485157
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of rush immunotherapy in patients with Hymenoptera allergy in Japan.
Hirata H; Asakura T; Arima M; Cheng G; Honda K; Fukushima F; Yamaguchi B; Yoshida N; Fukuda T
Asian Pac J Allergy Immunol; 2003 Jun; 21(2):89-94. PubMed ID: 14629126
[TBL] [Abstract][Full Text] [Related]
29. Safety of rush insect venom immunotherapy. The results of a retrospective study in 178 patients.
Wenzel J; Meissner-Kraemer M; Bauer R; Bieber T; Gerdsen R
Allergy; 2003 Nov; 58(11):1176-9. PubMed ID: 14616130
[TBL] [Abstract][Full Text] [Related]
30. Maintenance venom immunotherapy administered at a 3-month interval preserves safety and efficacy and improves adherence.
Cavallucci E; Ramondo S; Renzetti A; Turi MC; Di Claudio F; Braga M; Incorvaia C; Schiavone C; Ballone E; Di Gioacchino M
J Investig Allergol Clin Immunol; 2010; 20(1):63-8. PubMed ID: 20232775
[TBL] [Abstract][Full Text] [Related]
31. Maintenance venom immunotherapy administered at 3-month intervals is both safe and efficacious.
Goldberg A; Confino-Cohen R
J Allergy Clin Immunol; 2001 May; 107(5):902-6. PubMed ID: 11344360
[TBL] [Abstract][Full Text] [Related]
32. [Accelerated desensitization for hymenoptera venom allergy in 30 hours: efficacy and safety in 150 cases].
van der Brempt X; Ledent C; Mairesse M
Rev Med Brux; 1997 Jun; 18(3):120-4. PubMed ID: 9273600
[TBL] [Abstract][Full Text] [Related]
33. When can immunotherapy for insect sting allergy be stopped?
Müller UR; Ring J
J Allergy Clin Immunol Pract; 2015; 3(3):324-8; quiz 329-30. PubMed ID: 25956311
[TBL] [Abstract][Full Text] [Related]
34. Wasp Venom Immunotherapy in a Patient With Immune-Mediated Inflammatory Central Nervous System Disease: Is it Safe?
Nittner-Marszalska M; Kowal A; Szewczyk P; Guranski K; Ejma M
J Investig Allergol Clin Immunol; 2017; 27(2):127-129. PubMed ID: 28398199
[No Abstract] [Full Text] [Related]
35. Sublingual desensitization in patients with wasp venom allergy: preliminary results.
Patriarca G; Nucera E; Roncallo C; Aruanno A; Lombardo C; Decinti M; Pascolini L; Milani M; Buonomo A; Schiavino D
Int J Immunopathol Pharmacol; 2008; 21(3):669-77. PubMed ID: 18831935
[TBL] [Abstract][Full Text] [Related]
36. Exclusive Bee Venom Allergy: Risk Factors and Outcome of Immunotherapy.
Rosman Y; Nashef F; Cohen-Engler A; Meir-Shafrir K; Lachover-Roth I; Confino-Cohen R
Int Arch Allergy Immunol; 2019; 180(2):128-134. PubMed ID: 31216540
[TBL] [Abstract][Full Text] [Related]
37. [Influence of venom immunotherapy on anxiety level of being re-stung].
Sacha M; Czarnobilska E; Stobiecki M; Dyga W
Przegl Lek; 2012; 69(12):1261-5. PubMed ID: 23750435
[TBL] [Abstract][Full Text] [Related]
38. Ultrarush venom desensitization after systemic reactions during conventional venom immunotherapy.
Oren E; Chegini S; Hamilos DL
Ann Allergy Asthma Immunol; 2006 Nov; 97(5):606-10. PubMed ID: 17165267
[TBL] [Abstract][Full Text] [Related]
39. [Results of hyposensitization with bee and wasp venom].
Adolph J; Dehnert I; Fischer JF; Wenz W
Z Erkr Atmungsorgane; 1986; 166(1):119-24. PubMed ID: 3953108
[TBL] [Abstract][Full Text] [Related]
40. Analysis of safety, risk factors and pretreatment methods during rush hymenoptera venom immunotherapy.
Gorska L; Chelminska M; Kuziemski K; Skrzypski M; Niedoszytko M; Damps-Konstanska I; Szymanowska A; Siemińska A; Wajda B; Drozdowska A; Jutel M; Jassem E
Int Arch Allergy Immunol; 2008; 147(3):241-5. PubMed ID: 18594155
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
